284 related articles for article (PubMed ID: 20180858)
1. Towards a Brucella vaccine for humans.
Perkins SD; Smither SJ; Atkins HS
FEMS Microbiol Rev; 2010 May; 34(3):379-94. PubMed ID: 20180858
[TBL] [Abstract][Full Text] [Related]
2. Research progress in live attenuated Brucella vaccine development.
Wang Z; Wu Q
Curr Pharm Biotechnol; 2013; 14(10):887-96. PubMed ID: 24372253
[TBL] [Abstract][Full Text] [Related]
3. Lipopolysaccharide as a target for brucellosis vaccine design.
Conde-Álvarez R; Arce-Gorvel V; Gil-Ramírez Y; Iriarte M; Grilló MJ; Gorvel JP; Moriyón I
Microb Pathog; 2013 May; 58():29-34. PubMed ID: 23219811
[TBL] [Abstract][Full Text] [Related]
4. Molecular host-pathogen interaction in brucellosis: current understanding and future approaches to vaccine development for mice and humans.
Ko J; Splitter GA
Clin Microbiol Rev; 2003 Jan; 16(1):65-78. PubMed ID: 12525425
[TBL] [Abstract][Full Text] [Related]
5. Acellular vaccines for ovine brucellosis: a safer alternative against a worldwide disease.
Martins Rda C; Irache JM; Gamazo C
Expert Rev Vaccines; 2012 Jan; 11(1):87-95. PubMed ID: 22149711
[TBL] [Abstract][Full Text] [Related]
6. Over-expression of homologous antigens in a leucine auxotroph of Brucella abortus strain RB51 protects mice against a virulent B. suis challenge.
Rajasekaran P; Surendran N; Seleem MN; Sriranganathan N; Schurig GG; Boyle SM
Vaccine; 2011 Apr; 29(17):3106-10. PubMed ID: 21376799
[TBL] [Abstract][Full Text] [Related]
7. Rough vaccines in animal brucellosis: structural and genetic basis and present status.
Moriyón I; Grilló MJ; Monreal D; González D; Marín C; López-Goñi I; Mainar-Jaime RC; Moreno E; Blasco JM
Vet Res; 2004; 35(1):1-38. PubMed ID: 15099501
[TBL] [Abstract][Full Text] [Related]
8. Development and trial of vaccines against
Lalsiamthara J; Lee JH
J Vet Sci; 2017 Aug; 18(S1):281-290. PubMed ID: 28859268
[TBL] [Abstract][Full Text] [Related]
9. A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination.
Cassataro J; Pasquevich KA; Estein SM; Laplagne DA; Velikovsky CA; de la Barrera S; Bowden R; Fossati CA; Giambartolomei GH; Goldbaum FA
Vaccine; 2007 May; 25(22):4437-46. PubMed ID: 17442465
[TBL] [Abstract][Full Text] [Related]
10. Brucella: a Mr "Hide" converted into Dr Jekyll.
Gorvel JP
Microbes Infect; 2008 Jul; 10(9):1010-3. PubMed ID: 18664389
[TBL] [Abstract][Full Text] [Related]
11. Confronting the barriers to develop novel vaccines against brucellosis.
Oliveira SC; Giambartolomei GH; Cassataro J
Expert Rev Vaccines; 2011 Sep; 10(9):1291-305. PubMed ID: 21919619
[TBL] [Abstract][Full Text] [Related]
12. Brucellosis: Improved Diagnostics and Vaccine Insights from Synthetic Glycans.
Bundle DR; McGiven J
Acc Chem Res; 2017 Dec; 50(12):2958-2967. PubMed ID: 29219305
[TBL] [Abstract][Full Text] [Related]
13. Brucellosis: a re-emerging zoonosis.
Seleem MN; Boyle SM; Sriranganathan N
Vet Microbiol; 2010 Jan; 140(3-4):392-8. PubMed ID: 19604656
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates.
Todd TE; Tibi O; Lin Y; Sayers S; Bronner DN; Xiang Z; He Y
BMC Bioinformatics; 2013; 14 Suppl 6(Suppl 6):S3. PubMed ID: 23735014
[TBL] [Abstract][Full Text] [Related]
15. The advances in brucellosis vaccines.
Hou H; Liu X; Peng Q
Vaccine; 2019 Jul; 37(30):3981-3988. PubMed ID: 31176541
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of vaccination strategies against intranasal challenge with Brucella abortus in BALB/c mice.
Surendran N; Sriranganathan N; Lawler H; Boyle SM; Hiltbold EM; Heid B; Zimmerman K; Witonsky SG
Vaccine; 2011 Mar; 29(15):2749-55. PubMed ID: 21316499
[TBL] [Abstract][Full Text] [Related]
17. Laboratory animal models for brucellosis research.
Silva TM; Costa EA; Paixão TA; Tsolis RM; Santos RL
J Biomed Biotechnol; 2011; 2011():518323. PubMed ID: 21403904
[TBL] [Abstract][Full Text] [Related]
18. Brucella melitensis Rev. 1 and Brucella abortus 45-20 vaccines in goats: immunity.
Alton GG; Jones LM; García-Carrillo C; Trenchi A
Am J Vet Res; 1972 Sep; 33(9):1747-51. PubMed ID: 4626469
[No Abstract] [Full Text] [Related]
19. Selection of a Brucella vaccine strain of low residual virulence by chemical mutagenesis.
Zhao WR; Wendoso ; Hasi ; Qin YX; Weng W; Lu SL
J Med Microbiol; 1989 Oct; 30(2):143-8. PubMed ID: 2795638
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of the immunobiological properties of live brucellosis vaccines.
Salmakov KM; Fomin AM; Plotnikova EM; Safina GM; Galimova GM; Salmakova AV; Ivanov AV; Panin AN; Sklyarov OD; Shumilov KV; Klimanov AI
Vaccine; 2010 Oct; 28 Suppl 5():F35-40. PubMed ID: 20362201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
